Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gaxilose→

Gaxilose Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
14087-31-1
Molecular formula
C11H20O10
Molecular weight
312.27 g/mol
Drug class
Diagnostic substratelactase activity test agent
Mechanism of action
Gaxilose (4-galactosylxylose) is an orally administered synthetic disaccharide substrate for intestinal lactase. Hydrolysis by lactase releases D-xylose and galactose; measurement of D-xylose in serum or urine provides an indirect assessment of intestinal lactase activity.
Indications / reported uses
  • Diagnostic assessment of intestinal lactase activity and lactose malabsorption using a serum or urine xylose measurement after oral administration, where the test is available and validated.

Sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC6839734/ · https://www.catlab.cat/uploads/20250115/CI139_ENG.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gaxilose Environmental Risk Assessment (ERA) (the Gaxilose ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.